With $250M in Financing, AstraZeneca Spinout to Focus on Severe Autoimmune Diseases

AstraZeneca has spun off six pipeline candidates being developed by its MedImmune subsidiary into a new company that said today it will be funded with $250 million and focus on severe autoimmune diseases.Viela Bio said it has incorporated as an independent inflammation- and autoimmunity-focused biotechnology company. MedImmune will contribute three clinical and three preclinical potential new medicines to the new company, including inebilizumab, currently in Phase II development.Inebilizumab&mda